Академический Документы
Профессиональный Документы
Культура Документы
Delamanid
Novel drugs are presently or soon entering Phase III
trials for the treatment of MDR-TB.
Delamanid, a novel TB drug, developed by Otsuka,
was granted conditional approval by the European
Medicine Agency in April 2014. I
Information about this new drug however remains
limited, since it has only been through Phase IIb
trial and studies for safety and efficacy.
Assessment of delamanid
Considering
the global MDR-TB crisis,
the limited therapeutic options available for this life-
threatening condition,
the need to promote safe and responsible use of TB drugs,
WHO convened an Expert Group in April 2014 to review the
available evidence on the efficacy, safety and effectiveness of
delamanid, a new drug for the treatment of MDR-TB
Aim of the Expert Group to advise WHO on development of
interim recommendations on its use in conjunction with WHOrecommended MDR-TB treatment.
Based on this advice, WHO developed full interim guidance
approved by its Guidelines Review Committee. A similar process
whas followed in 2013 for bedaquiline
Also NEW:
WHO POLICY IMLEMENTATION PACKAGE for the
introduction of new TB drugs
GOAL: To support countries in preparing for introduction of new TB drugs and/or
regimens, based on WHO policy guidance, in order to better serve patients and
communities in need. There are six elements: